Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(41): 15358-15366 [PMID: 25386085 DOI: 10.3748/wjg.v20.i41.15358]
Corresponding Author of This Article
Ece Mutlu, MD, MS, MBA, Associate Professor, IBD Program Director, Department of Medicine, Clinical Research Section of Gastroenterology, Hepatology and Nutrition, Rush University, 1725 W. Harrison, Suite 206, Chicago, IL 60612, United States. ece_mutlu@rush.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 7, 2014; 20(41): 15358-15366 Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15358
Hepatitis B vaccination in patients with inflammatory bowel disease
Ruwaida Ben Musa, Anuhya Gampa, Sanjib Basu, Ali Keshavarzian, Garth Swanson, Michael Brown, Rana Abraham, Keith Bruninga, John Losurdo, Mark DeMeo, Sohrab Mobarhan, David Shapiro, Ece Mutlu
Ruwaida Ben Musa, Graduate College, Rush University, Chicago, IL 60612, United States
Anuhya Gampa, Rush University, Chicago, IL 60612, United States
Sanjib Basu, Department of Preventive Medicine, Rush University, Chicago, IL 60612, United States
Ali Keshavarzian, Garth Swanson, Michael Brown, Rana Abraham, Keith Bruninga, John Losurdo, Mark DeMeo, Sohrab Mobarhan, David Shapiro, Ece Mutlu, Department of Gastroenterology and Nutrition, Rush University, Chicago, IL 60612, United States
Ece Mutlu, Department of Medicine, Clinical Research Section of Gastroenterology, Hepatology and Nutrition, Rush University, Chicago, IL 60612, United States
Author contributions: Ben Musa R collected, analyzed, interpreted the data, and wrote the paper; Gampa A wrote project protocol, set up data collection database and collected part of the data; Basu S reviewed all the statistics; Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S and Shapiro D provided data and reviewed the manuscript; Mutlu E provided the hypotheses, designed the study, interpreted the data, supervised the data collection, analysis and wrote the paper; Mutlu E gave final approval of the version to be published.
Correspondence to: Ece Mutlu, MD, MS, MBA, Associate Professor, IBD Program Director, Department of Medicine, Clinical Research Section of Gastroenterology, Hepatology and Nutrition, Rush University, 1725 W. Harrison, Suite 206, Chicago, IL 60612, United States. ece_mutlu@rush.edu
Telephone: +11-312-563-3880 Fax: +11-312-563-3883
Received: November 23, 2013 Revised: May 31, 2014 Accepted: June 26, 2014 Published online: November 7, 2014 Processing time: 352 Days and 11.2 Hours
Core Tip
Core tip: With immunomodulatory drugs being used for treatment of inflammatory bowel disease (IBD) patients, it is important that IBD patients be protected against preventable infections, specifically hepatitis B. Compared to previous literature, the prevalence of hepatitis B virus (HBV) in IBD patients in a large tertiary gastroenterology practice in the United States was not higher than Europe. However, a significant portion of IBD patients were not routinely screened and vaccinated against HBV at a large tertiary gastroenterology practice. This corroborates the need for gastroenterologists and primary care physicians to be cognizant of treating IBD patients for preventable diseases in addition to managing IBD itself. Further education and use of electronic record prompters may be needed to increase prevention of HBV.
